Egetis Board Recommends ANI Pharmaceuticals’ Cash Offer
Egetis Therapeutics’ board recommends ANI Pharmaceuticals’ cash offer.
Related stories
Commerzbank Says UniCredit Deal Could Create Value
Commerzbank’s CEO said the lender was convinced a deal with UniCredit could create value. The statement came as Commerzbank reported a 45% increase in third-quarter profit.
M impact | MNA | Nov 05, 2026, 06:18 AM UTC
Egetis board unanimously recommends ANI cash offer at SEK 11.25 per share
Egetis’ board unanimously recommends ANI’s cash offer of SEK 11.25 per share, valuing the offer at approximately SEK 5,304M; holders of approximately 42.2% of outstanding shares ag
M impact | MNA | Nov 05, 2026, 06:16 AM UTC
Samsung Biologics Reaches a Definitive Stake in PolyPeptide
Samsung Biologics has reached a definitive stake in PolyPeptide.
M impact | MNA | Nov 05, 2026, 06:15 AM UTC
China blocks billion-dollar ABB robotics deal
Reuters reports that China is blocking a billion-dollar deal involving ABB robotics.
M impact | MNA | Nov 05, 2026, 06:15 AM UTC
Dong-A Pharmaceutical Unit to Sell D&T Holding Stake for KRW 39.87 Billion
A Dong-A Pharmaceutical unit will sell its stake in D&T Holding for KRW 39.87 billion.
M impact | MNA | Nov 05, 2026, 06:11 AM UTC
Merko Ehitus Sells 70% Stake in Rūdninkai Campus Project Companies
Merko Ehitus sold a 70% stake in the companies behind the Rūdninkai military campus project to Kapitel.
M impact | MNA | Nov 05, 2026, 06:11 AM UTC